1 / 1

Advanced Tumor-Specific Radioactive Activity for Optimal Treatment Efficacy

Discover how different radionuclides deliver varying absorbed doses to the renal cortex for maximum therapeutic benefit, with a focus on achieving a Tumor Control Probability of 0.9. Explore the implications of specific activities like 177Lu, 125Sn, and 177Y on treatment outcomes.

yvonne-gilliam
Download Presentation

Advanced Tumor-Specific Radioactive Activity for Optimal Treatment Efficacy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ≈250Gy 200Gy ≈ tumor specific activity giving TCP=0.9 [MBq/ml] ≈130Gy 0.00 0.00 1.00 1.00 0.20 0.80 0.20 0.80 0.60 0.60 0.40 0.40 0.60 0.40 0.40 0.60 0.80 0.20 0.80 0.20 0.00 0.00 1.00 1.00 90Y 177Lu 125Sn renal cortex absorbed dosefraction per radionuclide (BED=33Gy)

More Related